NCT01215799View on ClinicalTrials.gov

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

December 31, 2011

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

Bafetinib

Bafetinib 240 mg bid

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

Sponsors

Lead Sponsor

CytRx
All Listed Sponsors
lead

CytRx

INDUSTRY

NCT01215799 - Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter